In This Article:
The JPMorgan Healthcare Conference is a place where deals happen. As the conference kicked off, deals were announced from Eli Lilly (LLY), Johnson & Johnson (JNJ), and GSK (GSK).
Maurits Pot, CEO of Tema ETFs, joins Market Domination to give his predictions for continued M&A growth, specifically within the oncology, neuroscience, and metabolic sectors.
Pot reflects on the challenges faced by the healthcare sector in 2024 and the outlook for the coming year.
"2024 was, again, a pretty muted year for healthcare M&A, overall, a muted year for the healthcare sector and a number of big companies did not do many big acquisitions," Pot's says. "We think there will be a material pick up this year."
Pot also discusses challenges in the GLP-1 market but cites innovation in drug delivery.
To watch more expert insights and analysis on the latest market action, check out more Market Domination here.
This post was written by Josh Lynch